Blau Farmaceutica SA
BOVESPA:BLAU3

Watchlist Manager
Blau Farmaceutica SA Logo
Blau Farmaceutica SA
BOVESPA:BLAU3
Watchlist
Price: 12 BRL -2.12% Market Closed
Market Cap: 2.2B BRL
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+51%
Revenue
Forecast
+13%
Operating Income
Forecast
+20%
Net Income
Forecast
+20%

Wall Street
Price Targets

BLAU3 Price Targets Summary
Blau Farmaceutica SA

Wall Street analysts forecast BLAU3 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BLAU3 is 18.09 BRL with a low forecast of 14.14 BRL and a high forecast of 23.63 BRL.

BLAU3 Lowest Forecast
Wall Street Target
14.14 BRL
18% Upside
BLAU3 Average Forecast
Wall Street Target
18.09 BRL
51% Upside
BLAU3 Highest Forecast
Wall Street Target
23.63 BRL
97% Upside
Lowest
Price Target
14.14 BRL
18% Upside
Average
Price Target
18.09 BRL
51% Upside
Highest
Price Target
23.63 BRL
97% Upside
Blau Farmaceutica SA Competitors:
Price Targets
B
BAVA
Bavarian Nordic A/S
14% Upside
VITR
Vitrolife AB
48% Upside
GMAB
Genmab A/S
41% Upside
C
CMPX
Compass Therapeutics Inc.
321% Upside
B
BAVA
Bavarian Nordic A/S
14% Upside
VITR
Vitrolife AB
48% Upside
GMAB
Genmab A/S
41% Upside
C
CMPX
Compass Therapeutics Inc.
321% Upside
BRNS
Barinthus Biotherapeutics PLC
264% Upside
AZT
Arcticzymes Technologies ASA
1% Upside
RIGL
Rigel Pharmaceuticals Inc
6% Downside
A
ACLX
Arcellx Inc
64% Upside

Revenue
Forecast

Revenue Estimate
Blau Farmaceutica SA

For the last 7 years the compound annual growth rate for Blau Farmaceutica SA's revenue is 16%. The projected CAGR for the next 3 years is 13%.

16%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Blau Farmaceutica SA

For the last 7 years the compound annual growth rate for Blau Farmaceutica SA's operating income is 10%. The projected CAGR for the next 3 years is 20%.

10%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Blau Farmaceutica SA

For the last 7 years the compound annual growth rate for Blau Farmaceutica SA's net income is 11%. The projected CAGR for the next 3 years is 20%.

11%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

See Also

Summary
BLAU3 intrinsic value, competitors valuation, and company profile.
DCF Valuation
BLAU3 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BLAU3 stock valuation using valuation multiples.
Wall Street Estimates
BLAU3 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BLAU3 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BLAU3's stock price target?
Price Target
18.09 BRL

According to Wall Street analysts, the average 1-year price target for BLAU3 is 18.09 BRL with a low forecast of 14.14 BRL and a high forecast of 23.63 BRL.

What is Blau Farmaceutica SA's Revenue forecast?
Projected CAGR
13%

For the last 7 years the compound annual growth rate for Blau Farmaceutica SA's revenue is 16%. The projected CAGR for the next 3 years is 13%.

What is Blau Farmaceutica SA's Operating Income forecast?
Projected CAGR
20%

For the last 7 years the compound annual growth rate for Blau Farmaceutica SA's operating income is 10%. The projected CAGR for the next 3 years is 20%.

What is Blau Farmaceutica SA's Net Income forecast?
Projected CAGR
20%

For the last 7 years the compound annual growth rate for Blau Farmaceutica SA's net income is 11%. The projected CAGR for the next 3 years is 20%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 274,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.